Immuno-oncology

#Biologics / Biotechnology #Cancer immunotherapy #Drug discovery #Flow Cytometry #Immuno-oncology #Webinar

Are you investigating pharmacological reactions?

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells. … Read More

#News

#Biosciences #Cancer research #Immuno-oncology #Oncology

Platform to improve predictability of immuno-oncology drugs 

Crown Bioscience has launched its ‘3D Ex Vivo Patient Tissue Platform’ which, using freshly collected patient tumour material, can accurately measure oncology and immuno-oncology drug-induced tumour killing and endogenous immune cell proliferation in a high throughput format.   Researchers presented data on the new platform at 2021’s AACR-NCI-EORTC International Conference on Molecular Targets and… Read More

#News

#Biology #Cancer research #Immuno-oncology #Systems biology #Therapeutics #Webinar

Targeted protein degradation: learn from an expert 

Challenges and Opportunities in Protein Degradation, is free webinar hosted by DDW and supported by Cell Signaling Technology (CST). It took place on 21 October, 2021 and is now available to watch on demand for free here.   Dr. Nathanael Gray, Professor of… Read More

#News

#Cancer immunotherapy #Flow Cytometry #Immuno-oncology #Webinar

Addressing bottlenecks in immuno-oncology therapies 

Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients.  On 4 November 2021, 9AM PT; 12PM ET; 4PM… Read More

#News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Deriving context from immunological data with flow cytometry – Webinar

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

#Cancer immunotherapy #Cancer research #Drug discovery #Immuno-oncology #Systems biology #Therapeutics #Webinar

Event examines emerging strategy for cancer therapeutic development 

In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD).  Challenges and Opportunities in Protein Degradation, took place on… Read More

#News

#Biosciences #CRO #Drug development #Immuno-oncology #Oncology

High demand for preclinical expertise fuels growth for Nottingham CRO 

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology,… Read More

#News

#AI #Drug development #Immuno-oncology #Machine learning #Oncology

Bristol Myers Squibb develops Exscientia’s drug candidate 

Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.  The in-licensed candidate targets… Read More

#Cancer Research #News

#Cancer immunotherapy #Cancer research #Clinical trials #Immuno-oncology #Immunology / Virology & Vaccines #Tumour biology

Collaboration to develop a novel cancer immunotherapy  

Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More

#Cancer Research #News

#Immuno-oncology #Oncology #Pharma #Tumour biology

BridgeBio collaborates with Bristol Myers Squibb

BridgeBio Pharma has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO (nivolumab) in patients with advanced solid tumours with KRAS mutations with the hope of providing an effective new treatment option for patients with difficult-to-treat cancers.  The… Read More

#Cancer Research #News

#Cancer research #Clinical trials #Immuno-oncology #Oncology

Belarus adds hormone-resistant prostate and breast cancers to study  

The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology’s Elenagen, an experimental DNA therapy, to include hormone-resistant breast cancer and hormone-resistant metastatic prostate cancer.  The decision to add two more deadly diseases to the ongoing study was based on encouraging preliminary results… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Exscientia #Immuno-oncology

Spotlight: AI in drug discovery first

Earlier this year, Exscientia announced what was said to be the first AI-designed immuno-oncology drug to enter clinical trials. Lu Rahman talks to CEO Andrew Hopkins about the company’s work and use of AI in drug discovery. LR:  How AI has been used in this process and what benefits has… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Drug development #Drug discovery #Immuno-oncology #Infectious diseases #Neurodegenerative disorders

This week in drug discovery (26-29 July)

News round-up by DDW’s Megan Thomas for 26-19 July DDW’s Megan Thomas rounds up her top five stories this week which show how innovation in drug discovery is enhanced by collaboration, be it financial backing or through the combining of differing expertise to achieve a common goal. SARS-CoV-2 spike… Read More

#News #Trending News

#Cancer immunotherapy #Cancer research #Immuno-oncology #Immunology #Tumour biology

Cancer project enters Immuno-oncology Alliance

In the UK, researchers Professor Andrew Beggs and Professor Gary Middleton from the Institute of Immunology and Immunotherapy and the Institute of Cancer and Genomic Sciences have partnered with Cancer Research UK in a target identification project for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer… Read More

#Cancer Research #News

#CAR-T #Drug discovery #Immuno-oncology #Immunotherapy #Institute of Cancer Research

Immune checkpoint inhibitors: What are the risks?

Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important… Read More

#Cancer Research #Exclusive Content #News

#Cancer research #CAR-T #Cell therapy #Drug development #Immuno-oncology

Innovation driving cell therapies toward the clinic

Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL). Since then,… Read More

#Exclusive Content #News